A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-01-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsbrainctcanceradequate
  Phrases that lowered it: screeningmalefemalehistoryinclusive
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 14.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 96.7% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports before start: 4877 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety Study of Nicardipine to Treat Cerebral Vasospasm NCT01810302 · started 2013 · scored riskier than 99% of active trials terminated
• Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage NCT02222727 · started 2014 · scored riskier than 62% of active trials terminated
• Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage NCT01893190 · started 2013 · scored riskier than 92% of active trials completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage NCT00940095 · started 2009 · scored riskier than 97% of active trials terminated
• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain NCT03585270 · started 2019 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.